A new chapter in the treatment of attention and mood has quietly opened at the American pharmacy counter, where centanafadine — sold as Simtriyo — becomes the first ADHD medication to engage dopamine, noradrenaline, and serotonin simultaneously. Approved by the FDA for adults and children six and older, it arrives not as a revolution but as an expansion of possibility, offering another path for those whose minds have not found peace with existing options. Its full place in the human story of psychiatric care remains unwritten, pending the slower work of real-world experience, comparative resea
New ADHD drug targets three brain chemicals, offering alternative to existing stimulants
More of these chemicals available for longer, helping brain cells communicate.
Mark
Why does it matter that this drug hits three brain chemicals instead of two?
Mimi
Because not everyone's brain responds the same way to the same treatment. If dopamine and noradrenaline alone don't work for you, adding serotonin into the mix might. It's another tool in the toolbox.
Mark
But we don't actually know if it works better than what we already have?
Mimi
Right. The trials compared it to placebo, not to existing drugs. So we know it works better than nothing, but we can't say it's superior to methylphenidate or the others yet.
Mark
Is it a stimulant or not?
Mimi
That's genuinely unclear. The company said non-stimulant, the FDA says stimulant. Probably the distinction matters less than how it actually behaves in someone's brain.
Mark
Could it help with depression too?
Mimi
Possibly. Because it touches serotonin, there's real interest in whether it could help people who have both ADHD and depression or anxiety. But we're still early—the research isn't finished.
Mark
Why isn't it available in Australia yet?
Mimi
It hasn't passed the Australian regulatory process. The TGA has to approve it before it can even be considered for subsidies through the PBS. That takes time.
Mark
What worries you most about this drug?
Mimi
That we're approving it without head-to-head comparisons to existing treatments. We know it works, but we don't know how it stacks up. That's a gap that real-world use will eventually fill.
The Pulse
- For the first time, an ADHD medication reaches all three of the brain's key chemical messengers at once — a distinction that sets centanafadine apart from every treatment that came before it.
- The question of whether it is a stimulant or not remains contested between its maker and the FDA, a tension that quietly shapes how patients and prescribers will approach it.
- Four clinical trials confirmed symptom improvement and tolerability, but none pit centanafadine directly against existing ADHD drugs, leaving its true competitive standing uncertain.
- Side effects mirror those of other ADHD medications — reduced appetite, insomnia, dry mouth — and a warning about suicidal thoughts echoes the cautions already attached to similar treatments.
- Patients in Australia and beyond must wait, as the drug has not yet cleared international regulatory bodies, and its potential to help those carrying both ADHD and anxiety or depression remains a promising but unfinished line of inquiry.
A new chapter in the treatment of attention and mood has quietly opened at the American pharmacy counter, where centanafadine — sold as Simtriyo — becomes the first ADHD medication to engage dopamine, noradrenaline, and serotonin simultaneously. Approved by the FDA for adults and children six and older, it arrives not as a revolution but as an expansion of possibility, offering another path for those whose minds have not found peace with existing options. Its full place in the human story of psychiatric care remains unwritten, pending the slower work of real-world experience, comparative research, and regulatory decisions in countries still watching from a distance.
Centanafadine, now available in the United States under the brand name Simtriyo, is the first ADHD medication to slow the reabsorption of three neurotransmitters — dopamine, noradrenaline, and serotonin — rather than the two targeted by standard treatments. Approved by the FDA for adults and children as young as six, it works by keeping these chemical messengers in circulation longer, giving brain cells more time to communicate. The addition of serotonin, which governs mood, sleep, and appetite, is what makes it chemically distinct from methylphenidate, dexamfetamine, and even atomoxetine.
Whether centanafadine is a stimulant depends on who you ask — its developer once called it otherwise, while the FDA classifies it as one. The practical question, though, is simpler: does it help people who haven't responded well to existing options? Four pre-approval clinical trials suggest it does, with one study in teenagers showing symptom improvement within a week. The limitation is that all trials compared the drug to placebo, not to other ADHD medications, so its relative effectiveness remains an open question. An indirect comparison hinted at fewer side effects than lisdexamfetamine, but such comparisons carry inherent uncertainty.
The most commonly reported side effects — appetite loss, insomnia, dry mouth, headache — are familiar territory for ADHD treatment, and the prescribing information includes a standard warning about suicidal thoughts, consistent with similar medications. Ongoing monitoring will sharpen the safety picture as more patients use it.
For now, centanafadine is inaccessible in Australia and other countries awaiting regulatory approval. Researchers are also exploring whether its serotonin activity might make it useful for people managing ADHD alongside anxiety or depression — a common and difficult combination. That possibility remains promising but unproven, and the drug's true place in psychiatric care will only become clear through time, wider use, and the studies still to come.
A new medication for attention-deficit hyperactivity disorder has arrived in the American pharmacy: centanafadine, a once-daily tablet marketed as Simtriyo. It was approved by the U.S. Food and Drug Administration for adults and children six and older, though it remains unavailable in Australia and other countries awaiting regulatory clearance.
What sets centanafadine apart is its reach into the brain's chemical messenger system. Most ADHD drugs work by boosting dopamine and noradrenaline—two neurotransmitters involved in attention, motivation, and impulse control. Centanafadine does all that, but it also touches serotonin, the chemical that helps regulate mood, sleep, and appetite. It's the first ADHD medication to work on all three at once. The mechanism is straightforward: normally, after a neurotransmitter delivers its signal between brain cells, the brain reabsorbs it quickly. Centanafadine slows that reabsorption process, leaving more of these chemicals in circulation longer, giving cells more time to communicate. Think of it as intercepting a text message before it gets deleted.
There's some debate about whether centanafadine is technically a stimulant. The company that developed it called it a non-stimulant in 2017, but the FDA labels it as a stimulant in its official product information. The distinction matters less than the practical reality: it offers another option for people whose bodies don't respond well to existing treatments. Standard ADHD stimulants like methylphenidate and dexamfetamine work primarily on dopamine and noradrenaline. Centanafadine's addition of serotonin activity makes it chemically distinct, though whether that translates to better real-world outcomes remains unclear.
The drug is not an antidepressant, despite its serotonin activity. Common antidepressants focus heavily on serotonin alone or serotonin plus noradrenaline, but they don't boost dopamine enough to address ADHD's core symptoms. Centanafadine's three-pronged approach—hitting all three chemicals—is what separates it from that class. It also differs from Strattera (atomoxetine), another non-stimulant ADHD option that primarily increases noradrenaline with minimal dopamine or serotonin effects.
Four large clinical trials tested centanafadine before FDA approval, and all showed symptom improvement and generally good tolerability. One study in teenagers found ADHD symptoms improved within about a week of starting the medication. But here's the catch: these trials compared centanafadine against placebo, not against existing ADHD drugs like methylphenidate or atomoxetine. So we cannot yet say whether it works better than what's already available. Researchers have published their own ratings of symptom improvement, but less information exists about how patients themselves felt the drug affected them. One indirect comparison—looking at centanafadine trials alongside previous studies of other medications—suggested it might cause less insomnia, anxiety, dry mouth, and appetite loss than lisdexamfetamine, but indirect comparisons require careful interpretation.
The most common side effects reported include reduced appetite, insomnia, dry mouth, and headache—effects that can occur with other ADHD medications too. The prescribing information carries a warning about suicidal thoughts and behaviors, a caution applied to other ADHD and depression treatments as well. As more people use the drug, researchers and the manufacturer will continue monitoring for safety signals.
Centanafadine has not yet been approved by Australia's Therapeutic Goods Administration or listed on its Pharmaceutical Benefits Scheme, meaning it remains inaccessible there. If it clears that regulatory hurdle, it could enter standard treatment pathways.
Because centanafadine affects serotonin alongside dopamine and noradrenaline, researchers are exploring whether it might help people with ADHD plus anxiety or depression—conditions that often occur together. Early research has shown promise, though full findings from studies examining ADHD and anxiety have not yet been published. Real-world experience and additional research will clarify where centanafadine fits in the treatment landscape, especially for patients juggling multiple psychiatric conditions.
Notable Quotes
We cannot yet say if centanafadine works better than existing ADHD medicines— Clinical evidence gap noted in regulatory review
Want the full story?
Read the original at The Conversation ↗
Health & Medicine